2,2-二甲基-2,3-二羟基-1-苯并呋喃-7-甲醛 | 38002-88-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 香豆素
• 中文名称: 2,2-二甲基-2,3-二羟基-1-苯并呋喃-7-甲醛
• 中文别名: 2,2-二甲基-2,3-二氢-1-苯并呋喃-7-甲醛
• 英文名称: 2,2-dimethyl-2,3-dihydrobenzofuran-7-carbaldehyde
• 英文别名: 2,3-dihydro-2,2-dimethylbenzofuran-7-carboxaldehyde；2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-carbaldehyde；2,2-dimethyl-3H-1-benzofuran-7-carbaldehyde
• CAS: 38002-88-9
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD04115387
• 分子量: 176.215
• InChiKey: HGKYVFOYQUSRQN-UHFFFAOYSA-N

物化性质

• 熔点：
  81 °C

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 安全说明：
  S24/25
• 海关编码：
  2932999099

SDS

Name:	2 2-Dimethyl-2 3-dihydro-1-benzofuran-7-carbaldehyde 97% Material Safety Data Sheet
Synonym:
CAS:	38002-88-9

Section 1 - Chemical Product MSDS Name:2 2-Dimethyl-2 3-dihydro-1-benzofuran-7-carbaldehyde 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
38002-88-9	2,2-Dimethyl-2,3-dihydro-1-benzofuran-	97%	unlisted

Hazard Symbols: None Listed.
Risk Phrases: None Listed.

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Not available.
Potential Health Effects
Eye:
May cause eye irritation.
Skin:
May cause skin irritation. May be harmful if absorbed through the skin.
Ingestion:
May cause irritation of the digestive tract. May be harmful if swallowed.
Inhalation:
May cause respiratory tract irritation. May be harmful if inhaled.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid.
Skin:
Get medical aid. Flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Get medical aid. Wash mouth out with water.
Inhalation:
Remove from exposure and move to fresh air immediately.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use water spray, dry chemical, carbon dioxide, or chemical foam.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container.

---

Section 7 - HANDLING and STORAGE
Handling:
Avoid breathing dust, vapor, mist, or gas. Avoid contact with skin and eyes.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Store under an inert atmosphere.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 38002-88-9: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Solid
Color: Not available.
Odor: Not available.
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: 81 - 82 deg C
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C11H12O2
Molecular Weight: 176.21

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Nitrogen oxides, carbon monoxide, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 38002-88-9 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
2,2-Dimethyl-2,3-dihydro-1-benzofuran-7-carbaldehyde - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
No information available.
IMO
No information available.
RID/ADR
No information available.

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: Not available.
Risk Phrases:
Safety Phrases:
S 24/25 Avoid contact with skin and eyes.
WGK (Water Danger/Protection)
CAS# 38002-88-9: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 38002-88-9 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 38002-88-9 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  2,2-二甲基-2,3-二羟基-1-苯并呋喃-7-甲醛 在 盐酸 、 sodium borohydrid 、 sodium chloride 作用下， 以 乙醇 、 水 为溶剂， 生成 (2,2-二甲基-2,3-二氢-1-苯并呋喃-7-基)甲醇
  参考文献：
  名称：

  S-trifluorobutenyl derivatives and pesticidal uses thereof

  摘要：

  化学式为##STR1##的S-三氟丁烯基硫代碳酸酯及其盐，其中X为R.sup.1 N或S，Y为RS或R.sup.3 R.sup.2 N；其中R为金属或从烷基、环烷基烷基、卤代环烷基烷基、烯基、卤代烷基、卤代烯基、炔基、烷氧基烷基、烷基硫基烷基、烷氧羰基烷基、卤代苯氧基烷基、三烷基硅烷基烷基、(乙烯基)二烷基硅烷基、(丙烯基)二烷基硅烷基、2-氯硫代吡啶-5-基甲基、苯基烷基、卤代苯基烷基、硝基苯基烷基、卤代烷基苯基烷基、二烷基-2,3-二氢苯并呋喃-7-基、[2-甲基-(1,1'-联苯)-3-基]甲基、3-苯氧基苄、苯硫基烷基、卤代苯硫基烷基、二烷基磷酰基、二烷基硫代磷酰基、二烷基异噁唑基烷基和噻唑基异噁唑基烷基；其中R.sup.1为烷基、环烷基、氰基、二烷基-2,3-二氢苯并呋喃-7-基、卤代苯基、卤代苯基烷基、卤代烷氧基苯基、吡啶基、卤代吡啶基、烷基-1,3,4-噻二唑基、卤代烷基-1,3,4-噻二唑基、苯并噻唑基、二烷氧唑基或噻唑啉基；其中R.sup.2为氢或烷基；其中R.sup.3为烷基、卤代烷基、环烷基、环烷基烷基、二烷基氨基烷基、二烷基-2-噁唑基、2-噻唑啉基、2-苯并噻唑基、4-苯基-2-噻唑基、烷基-1,3,4-噻二唑基、卤代烷基-1,3,4-噻二唑基、吡啶基、卤代吡啶基、苯基、卤代苯基、卤代苯基烷基、卤代烷氧基苯基或二烷基-2,3-二氢苯并呋喃-7-基；条件是：当X为S时，Y为R.sup.3 R.sup.2 N；当X为R.sup.1 N时，Y为RS，R.sup.1不是烷基且R不是卤代烯基；当X为R.sup.1 N且R.sup.1为CN时，Y为RS，R不是碱金属。这些化合物表现出线虫杀和驱虫活性，并在农业和兽医实践中有用。

  公开号：

  US04748186A1
• 作为产物：
  描述：

  呋喃酚 在 吡啶 、 1,1'-双(二苯基膦)二茂铁 、 palladium diacetate 、 重铬酸吡啶 、 二异丁基氢化铝 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 二甲基亚砜 、 甲苯 为溶剂， 反应 17.5h， 生成 2,2-二甲基-2,3-二羟基-1-苯并呋喃-7-甲醛
  参考文献：
  名称：

  New Diarylmethylpiperazines as Potent and Selective Nonpeptidic δ Opioid Receptor Agonists with Increased In Vitro Metabolic Stability

  摘要：

  Nonpeptide delta opioid agonists are analgesics with a potentially improved side-effect and abuse liability profile, compared to classical opioids. Andrews analysis of the NIH nonpeptide lead SNC-80 suggested the removal of substituents not predicted to contribute to binding. This approach led to a simplified lead, N,N-diethyl-4-[phenyl( 1-piperazinyl)methyl]benzamide (1), which retained potent binding affinity and selectivity to the human delta receptor (IC50 = 11 nM, mu/delta = 740, kappa/delta > 900) and potency as a full agonist (EC50 = 36 nM) but had a markedly reduced molecular weight, only one chiral center, and increased in vitro metabolic stability. From this lead, the key pharmacophore groups for delta receptor affinity and activation were more clearly defined by SAR and mutagenesis studies. Further structural modifications on the basis of 1 confirmed the importance of the N,N-diethylbenzamide group and the piperazine lower basic nitrogen for delta binding, in agreement with mutagenesis data. A number of piperazine N-alkyl substituents were tolerated. In contrast, modifications of the phenyl group led to the discovery of a series of diarylmethylpiperazines exemplified by N,N-diethyl-4-[1-piperazinyl(8-quinolinyl)- methyl]benzamide (56) which had an improved in vitro binding profile (IC50 = 0.5 nM, mu/delta = 1239, EC50 = 3.6 nM) and increased in vitro metabolic stability compared to SNC-80.

  DOI：

  10.1021/jm000228x

文献信息

• Substituted Pyrrolidines and Methods of Use
  申请人：AbbVie S.à.r.l.

  公开号：US20180099931A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R 1 , R 2 , R 2A , R 3 , R 3A , R 4 , R 4A , and R 5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  该发明公开了式（I）的化合物 其中R 1 ，R 2 ，R 2A ，R 3 ，R 3A ，R 4 ，R 4A 和R 5 如本文所定义。本发明涉及化合物及其在囊性纤维化治疗中的应用，其生产方法，包含相同化合物的药物组合物，以及通过给予该发明的化合物来治疗囊性纤维化的方法。
• Novel compounds
  申请人：——

  公开号：US20030105110A1

  公开（公告）日：2003-06-05

  Compounds of general formula (I), wherein R 1 selected from phenyl, pyridinyl, thiophenyl, furanyl, imidazolyl, and triazolyl; where each R 1 phenyl ring and R 1 heteroaromatic ring may optionally and independently be further substituted by 1, 2 or 3 substituents selected from straight and branched C 1 -C 6 alkyl, NO 2 , CF 3 , C 1 -C 6 alkoxy, chloro, fluoro, bromo, and iodo.

  通式（I）的化合物，其中R1选自苯基、吡啶基、噻吩基、呋喃基、咪唑基和三唑基；其中每个R1苯环和R1杂环可能且独立地进一步被1、2或3个取自直链和支链C1-C6烷基、NO2、CF3、C1-C6烷氧基、氯、氟、溴和碘的取代基所取代。
• RENIN INHIBITORS
  申请人：Gwaltney Stephen L.

  公开号：US20100137310A1

  公开（公告）日：2010-06-03

  The invention provides compounds, pharmaceutical compositions, kits, method of preparing, and method of using the compounds which exhibit renin and other S9 proteases activities and consist of the formula:—wherein the variables are as defined herein.

  这项发明提供了一种具有肾素和其他S9蛋白酶活性的化合物、药物组合物、试剂盒、制备方法和使用该化合物的方法，其化学式为：—其中变量如本文所定义。
• General Asymmetric Synthesis of Densely Functionalized Pyrrolidines via <i>Endo</i>-Selective [3+2] Cycloaddition of β-Quaternary-Substituted Nitroalkenes and Azomethine Ylides
  作者：Stephen N. Greszler、Gang Zhao、Marek Buchman、Xenia B. Searle、Bo Liu、Eric A. Voight

  DOI：10.1021/acs.joc.0c00820

  日期：2020.6.5

  5-tetrasubstituted pyrrolidines via cycloaddition of nitroalkenes and azomethine ylides is reported using a P,N-type ferrocenyl ligand and [Cu(OTf)]2·C6H6. The robust method is tolerant of a wide range of functionalities, including rarely reported quaternary nitroalkene substitution and heteroaromatic and hindered ortho-substituted arenes on the azomethine ylide. Subsequent transformations highlight

  一种可分级内的通过硝基烯烃和甲亚胺叶立德的环加成2,3,4,5-四取代的吡咯烷-选择性合成是使用P，N型二茂铁基配体报告和[铜（OTF）] 2 ·C 6 H ^ 6。稳健的方法可耐受多种功能，包括很少报道的季硝基链烯取代以及在甲亚胺叶立德上的杂芳族和受阻邻位取代的芳烃。随后的转化突出了该方法在合成适合基于片段的药物发现和囊性纤维化C2校正临床候选ABBV-3221的密集功能化小分子中的实用性。
• [EN] SUBSTITUTED PYRROLIDINES AS CFTR MODULATORS<br/>[FR] PYRROLIDINES SUBSTITUÉES EN TANT QUE MODULATEURS DE CFTR
  申请人：ABBVIE SARL

  公开号：WO2018065921A1

  公开（公告）日：2018-04-12

  The invention discloses compounds of Formula (I) wherein R1, R2, R2A, R3, R3A, R4, and R5 are as defined herein. The present invention relates to compounds and their use in the treatment of cystic fibrosis, methods for their production, pharmaceutical compositions comprising the same, and methods of treating cystic fibrosis by administering a compound of the invention.

  本发明公开了式(I)的化合物，其中R1，R2，R2A，R3，R3A，R4和R5如本文所定义。本发明涉及化合物及其在囊性纤维化病治疗中的应用，制备它们的方法，包含它们的制药组合物，以及通过给予本发明的化合物治疗囊性纤维化病的方法。